ORKA Oruka Therapeutics Inc.

$ORKA Great data so far with 001-looking forward to the -002 data release and the initiation of -004. Blockbuster!

Today on the calendar: $ORKA drops Phase 2b psoriasis data this morning, $IOVA presents lifileucel sarcoma data, and the BOLT financing is set to close and the week ahead is all about Friday, $INO has its Oct 30 date for INO 3107 and $AGIO follows Nov 1 for mitapivat in sickle cell, Sunday date so Friday is the real window

$ORKA will host a conference call to present Week 16 data from its EVERLAST-B Phase 2b trial on Oct 26.

6-K/8-K Important Update $ORKA Oruka Therapeutics, Inc. reported positive Week 16 results from its Phase 2b EVERLAST-B trial of ORKA-001, an investigational IL-23p19 monoclonal antibody, for moderate-to-severe plaque psoriasis. In the trial, 61% of patients receiving 600 mg achieved PASI 100, significantly surpassing the placebo group (p<0.0001). The company plans to commence Phase 3 trials in early 2027 and anticipates releasing 52-week results in December 2026.

6-K/8-K Important Update $ORKA Oruka Therapeutics, Inc. reported positive Week 16 results from its Phase 2b EVERLAST-B trial of ORKA-001, an investigational IL-23p19 monoclonal antibody, for treating moderate-to-severe plaque psoriasis. In the trial, 61% of patients receiving 600 mg achieved PASI 100, significantly outperforming the placebo group (p<0.0001), with a favorable safety profile noted. The company intends to begin Phase 3 trials in early 2027, pending regulatory discussions.

$ORKA 🏥 Oruka Therapeutics, Inc. announced Week 16 results from its Phase 2b EVERLAST-B trial of ORKA-001 in 187 patients with moderate-to-severe psoriasis, with PASI 100 at Week 16 as the primary endpoint. Prioritized by relevance

$ORKA Oruka's 600 mg psoriasis dose cleared skin in 61% at Week 16 with no serious side effects. 🏢 Oruka Therapeutics is a clinical-stage biotech developing ORKA-001, a long-acting IL-23p19 antibody for psoriasis meant to be dosed once or twice a year 📈 That is the dose Oruka plans to take into Phase 3, and 61% of its patients reached fully clear skin (PASI 100) versus 0% on placebo (p<0.0001), close to the 63.5% EVERLAST-A showed in April 🏦 Oruka held $1.13B in cash and investments at June 30, 2026, against a roughly $5.31B market value at $80.15 (16:00 ET, Oct 23, 2026) ⚠️ The bear case is that 16 weeks cannot prove the durability behind once-a-year dosing, the mid dose nearly matched on PASI 90 (85% vs 86%), and Phase 3 still waits on regulator talks 📅 Next: EVERLAST-A 52-week results in December 2026, then ORKA-002's ORCA-SURGE Week 16 data in 1Q 2027 Source: GlobeNewswire release, Oct 26 + SEC 8-K, Aug 10

$ORKA 🏥 Oruka Therapeutics, Inc. announced positive Week 16 EVERLAST-B results for ORKA-001 in moderate-to-severe psoriasis, with 61% PASI 100 and 86% PASI 90 in the 600 mg high-dose group. Prioritized by relevance

$ORKA Data release coming here tomorrow. Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 "today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results."

Latest SEC filing, October 15, 2026: Oruka's chief medical officer sold 7,000 shares after exercising options and warrants, and filed a notice for a further 21,000 shares (Forms 4 and 144). Oruka Therapeutics ($ORKA): 71.4% PASI 100 At Week 28 Deeper dive in our hub. Not investment advice.